Ulrik Lassen, MD, PhD, discusses the updated response findings with larotrectinib in TRK+ cancers.
Ulrik Lassen, MD, PhD, professor, Department of Oncology, Rigshospitalet, Copenhagen, discusses the updated response findings with larotrectinib in TRK+ cancers.
In a pooled analysis of adult and pediatric patients with advanced cancers associated withNTRKgene fusions, the TRK inhibitor larotrectinib had an 80% objective response rate. The most recent follow-up data showed complete responses in 10 of 55 patients and partial responses in 34. This pooled analysis consisted of 3 studies in multiple tumor types and across the age range from infants to older adults.
According to Lassen, larotrectinib continues to demonstrate robust tumor-agnostic and age-agnostic antitumor activity against TRK fusion cancers, regardless of theNTRKgene or fusion partner involved. Although NTRK